【正文】
Thaddeus Grasela,美國Cognigen公司下午專題報告(Ⅰ):新藥研發(fā)及全球合作-法規(guī)科學(xué)、生物制劑研發(fā)Bridging Strategies to Support Global Drug Development:Regulatory Science;Biological Drug Development A Contemporary View of Bioequivalence and Therapeutic Equivalence生物等效性與治療等效性的現(xiàn)代思考Meilin Chen,美國國家食品藥品監(jiān)督管理局(FDA)PointstoConsider: Bioequivalence Studies vs. Biowaivers 生物利用度與生物等效性試驗需考慮的問題Renli Teng,美國AstraZenica公司Ethnic Factors in the Acceptability of Foreign Clinical Data:AntiHBV Drug臨床藥理學(xué)與藥物開發(fā)的有效結(jié)合-以新抗乙肝病毒藥物Sebivo為例Xiaojian Zhou,美國Idenix Pharmaceuticals, Biological Drug Development from Academic Perspective生物制藥開發(fā)-從學(xué)術(shù)角度Bernd Meibohm,美國田納西大學(xué)Biological Drug Development from Industrial Perspective生物制藥開發(fā)-從企業(yè)角度Diane Wang(王丹),美國輝瑞公司下午專題報告(Ⅱ):定量藥理學(xué)及藥代動力學(xué)在新藥研發(fā)中的應(yīng)用-基于模型的藥物開發(fā)、群體藥動學(xué)、PK/PD模型、臨床試驗?zāi)M Quantitative Pharmacology in Drug Development: Model based Drug Development 。 PK/PD Model。 Johnson)公司Model Based Analysis in Drug Drug Interaction基于模型的藥物相互作用分析Min Zhu(朱敏),美國BMS公司Quantitative Assessment of Drug Effect on QT Interval: Mixed Effect Modeling as a Practical Solution to Interpret Drug Effect in the Midst of High QT Variability 藥物效應(yīng)QT間期的定量評估:應(yīng)用混合效應(yīng)模型解釋高QT變異中的藥物效應(yīng)Charles Oo,美國Asubio Pharmaceuticals Integration Genetics to PK/PD Opportunities and Challenges 遺傳學(xué)與藥動學(xué)/藥效學(xué)的結(jié)合:機(jī)遇與挑戰(zhàn) Ophelia Yin,美國Novartis公司Status of PK/PD Modeling Research in China中國PK/PD模型的研究現(xiàn)狀及展望黃曉暉,安徽醫(yī)科大學(xué)藥學(xué)院晚上專題討論1. Improving the Process of Performing Modeling and Simulation Activities如何提高建模與模擬的過程2. Curriculum Development for the Next Generation Pharmaetrics Scientist 定量藥理學(xué)專家的培養(yǎng)及課程設(shè)計10月30日,周二上午大會報告Modern Research in Pharmacokinetics of Traditional Chinese Medicine中藥藥代動力學(xué)現(xiàn)代研究的思考劉昌孝,天津藥物研究院Integrating Modeling and Simulation Strategies into Targeted Translational Research建模與模擬策略在Targeted Translational研究中的應(yīng)用Jeffer